The emergence of willing sellers, a pullback in competition from strategic investors, and greater availability of leveraged financing are contributing to more buyout deal flow in China.
"The market is emerging in China, I wouldn't say it is mature," Frank Tang, chairman and CEO of FountainVest Partners, told the AVCJ Forum. "Most entrepreneurs are healthy and young, so for generational...
China-based data storage software services provider XSKY has raised a RMB320 million ($45 million) Series D led by China's State Owned Capital Venture Capital Fund.
CF PharmTech, a Chinese medical devices maker focused on innovative respiratory products, has raised a $50 million Series F round with support from CICC Capital.
Chinese insulin manufacturer Gan & Lee Pharmaceuticals, which counts Qiming Venture Partners and Goldman Sachs among its investors, raised RMB2.5 billion ($354 million) through an A-share IPO.
KKR has agreed to buy a 54% stake in Indian drug maker J.B. Chemicals & Pharmaceuticals for INR31.1 billion ($416 million) and made an open offer for an additional 26% of the company.